The European Commission has granted marketing authorisation for Tecentriq® SC, the EU’s first PD-(L)1 cancer immunotherapy for subcutaneous injection.
The European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union’s first PD-(L)1 cancer immunotherapy for subcutaneous injection. Roche announced that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union’s first PD-(L)1…